Arteriogenic gene therapy in patients with unreconstructable critical limb ischemia: A randomized, placebo-controlled clinical trial of adenovirus 5-delivered fibroblast growth factor-4

Human Gene Therapy

Volumn 16, Issue 10, 2005, Pages 1202-1211

  Matyas, L ^a   Schulte, K L ^b   Dormandy, J A ^c   Norgren, L ^d   Sowade, O ^e   Grotzbach G ^e   Palmer Kazen, Ulrika ^f   Rubanyi, G M ^g   Wahlberg, E ^f  

^a Borsod County Teaching Hospital   (Hungary)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c ST GEORGE S HOSPITAL   (United Kingdom)

^d ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

^e BAYER PHARMA AG   (Germany)

^f KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^g BAYER AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CONTRAST MEDIUM; FIBROBLAST GROWTH FACTOR 4; GADOLINIUM PENTETATE; GENE PRODUCT; NEUTRALIZING ANTIBODY; NUCLEAR MAGNETIC RESONANCE IMAGING AGENT; PLACEBO;

ADENOVIRUS 5; ADULT; AGED; ANGIOGENESIS; ARTICLE; BELOW KNEE AMPUTATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS; DIGITAL SUBTRACTION ANGIOGRAPHY; DOUBLE BLIND PROCEDURE; FEMALE; GENE CASSETTE; GENE EXPRESSION; GENE THERAPY; GENE TRANSFER; GENETIC TRANSFECTION; HUMAN; LEG REVASCULARIZATION; LIMB ISCHEMIA; MALE; MULTICENTER STUDY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PROMOTER REGION; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SAFETY; SCINTIANGIOGRAPHY; SEROTYPE; TREATMENT OUTCOME; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS GENOME; VIRUS RECOMBINANT;

ADENOVIRIDAE; AGED; AGED, 80 AND OVER; COHORT STUDIES; DOUBLE-BLIND METHOD; EXTREMITIES; FEMALE; GENE THERAPY; GENETIC VECTORS; HUMANS; INJECTIONS, INTRAMUSCULAR; ISCHEMIA; MALE; MIDDLE AGED;

ADENOVIRIDAE; HUMAN ADENOVIRUS TYPE 5;

EID: 26644444774     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.2005.16.1202     Document Type: Article

References (27)

1. ASAHARA, T., BAUTERS, C., ZHENG, L.P., TAKESHITA, S., BUNTING, S., FERRARA, N., SYMES, J.F., and ISNER, J.M. (1995). Synergistic effect of vascular endothelial growth factor and basic fibroblast growth factor on angiogenesis in vivo. Circulation 92, 11365-11371.
2. BAUMGARTNER, I., PIECZEK, A., MANOR, O., BLAIR, R., KEARNEY, M., WALSH, K., and ISNER, J.M. (1998). Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia. Circulation 97, 1114-1123.
3. BERGELSON, J.M., CUNNINGHAM, J.A., DROGUETT, G., KURT-JONES, E.A., KRITHIVAS, A., HONG, J.S., HORWITZ, M.S., CROWELL, R.L., and FINBERG, R. W. (1997). Isolation of a common receptor for coxsackie B viruses and adenoviruses 2 and 5. Science 275, 1320-1323.
4. BERTELE, V., RONCAGLIONI, M.C., PANGRAZZI, J., TERZIAN, E., and TOGNONI, E.G. (1999). Clinical outcome and its predictors in 1560 patients with critical leg ischaemia. Chronic Critical Leg Ischaemia Group. Eur. J. Vasc. Endovasc. Surg. 18, 401-410.
5. BRUNETTI-PIERRI, N., PALMER, D.J., BEAUDET, A.L., CAREY, K.D., FINEGOLD, M., and NG, P. (2004). Acute toxicity after high-dose systemic injection of helper-dependent adenoviral vectors into nonhuman primates. Hum. Gene Ther. 15, 35-46.
6. CAO, R., BRAKENHIELM, E., PAWLIUK, R., WARIARO, D., POST, M.J., WAHLBERG, E., LEBOULCH, P., and CAO, Y. (2003). Angiogenic synergism, vascular stability and improvement of hind-limb ischemia by a combination of PDGF-BB and FGF-2. Nat. Med. 9, 604-613.
7. DORMANDY, J., HEECK, L., and VIG, S. (1999). The fate of patients with critical leg ischemia. Semin. Vasc. Surg. 12, 142-147.
8. FALLAUX, F.J., BOUT, A., VAN DER VELDE, I., VAN DEN WOLLENBERG, D.J., HEHIR, K.M., KEEGAN, J., AUGER, C., CRAMER, S.J., VAN ORMONDT, H., VAN DER EB, A.J., VALERIO, D., and HOEBEN, R.C. (1998). New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication-competent adenoviruses. Hum. Gene Ther. 9, 1909-1917.
9. GALZIE, Z., KINSELLA, A.R., and SMITH, J.A. (1997). Fibroblast growth factors and their receptors. Biochem. Cell Biol. 75, 669-685.
10. GERWINS, P., SKOLDENBERG, E., and CLAESSON-WELSH, L. (2000). Function of fibroblast growth factors and vascular endothelial growth factors and their receptors in angiogenesis. Crit. Rev. Oncol. Hematol. 34, 185-194.
11. GRINES, C.L., WATKINS, M.W., HELMER, G., PENNY, W., BRINKER, J., MARMUR, J.D., WEST, A., RADE, J.J., MARROTT, P., HAMMOND, H.K., and ENGLER, R.L. (2002). Angiogenic GENe Therapy (AGENT) trial in patients with stable angina pectoris. Circulation 105, 1291-1297.
12. GRINES, C.L., WATKINS, M.W., MAHMARIAN, J.J., ISKANDRIAN, A.E., RADE, J.J., MARROTT, P., PRATT, C., and KLEIMAN, N. (2003). A randomized, double-blind, placebo-controlled trial of Ad5FGF-4 gene therapy and its effect on myocardial perfusion in patients with stable angina. Angiogene GENe Therapy (AGENT-2) Study Group. J. Am. Coll. Cardiol. 42, 1339-1347.
13. HARVEY, B.C., HACKETT, N.R., EL-SAWY, T., ROSENGART, T.K., HIRSCHOWITZ, E.A., LIEBERMAN, M.D., LESSER, M.L., and CRYSTAL, R.G. (1999). Variability of human systemic humoral immune responses to adenovirus gene transfer vectors administered to different organs. J. Virol. 73, 6729-6742.
14. JAMSEN, T., MANNINEN, H., TULLA, H., and MATSI, P. (2002). The final outcome of primary infrainguinal percutaneous transluminal angioplasty in 100 consecutive patients with chronic critical limb ischemia. J. Vasc. Interv. Radiol. 13, 455-463.
15. KREUGER, J., JEMTH, P., SANDERS-LINDBERG, E., ELIAHU, L., RON, D., BASILICO, C., SALMIVIRTA, M., and LINDAHL, U. (2005). Fibroblast growth factors share binding sites in heparan sulfate. Biochem. J. 389, 145-150.
16. LEDERMAN, R.J., MENDELSOHN, P.O., ANDERSON, R.D., SAUCEDO, J.F., TENAGLIA, A.N., HERMILLER, J.B., HILLEGASS, W.B., ROCHA-SINGH, K., MOON, T.E., WHITEHOUSE, M.J., and ANNEX, B.H. (2002). Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): A randomised trial. Lancet 359, 2053-2058.
17. LEPANTALO, M., and MATZKE, S. (1996). Outcome of unreconstructed chronic critical leg ischaemia. Eur. J. Vas. Endovasc. Surg. 11, 153-157.
18. NICKLIN, S.A., WHITE, S.J., NICOL, C.G., VON SEGGERN, D.J., and BAKER, A.H. (2004). In vitro and in vivo characterisation of endothelial cell selective adenoviral vectors. J. Gene Med. 6, 300-308.
19. RAJAGOPALAN, S., MOHLER, E.R., III, LEDERMAN, R.J., MENDELSOHN, F.O., SAUCEDO, J.F., GOLDMAN, C.K., BLEBEA, J., MACKO, J., KESSLER, P.D., RASMUSSEN, H.S., and ANNEX, B.H. (2003). Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease: A phase II randomized, double-blind, controlled study of adenoviral delivery of vascular endothelial growth factor 121 in patients with disabling intermittent claudication. Circulation 108, 1933-1938.
20. RISSANEN, T.T., VAJANTO, I., HILTUNEN, M.O., RUTANEN, J., KETTUNEN, M.I., NIEMI, M., LEPPANEN, P., TURUNEN, M.P., MARKKANEN, J.E., ARVE, K., ALHAVA, E., KAUPPINEN, R.A., and YLA-HERTTUALA, S. (2002). Expression of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 (KDR/Flk-1) in ischemic skeletal muscle and its regeneration. Am. J. Pathol. 160, 1393-1403.
21. RISSANEN, T.T., MARKKANEN, J.E., ARVE, K., RUTANEN, J., KETTUNEN, M.I., VAJANTO, I., JAUHIAINEN, S., CASHION, L., GRUCHALA, M., NARVANEN, O., TAIPALE, P., KAUPPINEN, R.A., RUBANYI, G.M., and YLA-HERTTUALA, S. (2003). Fibroblast growth factor 4 induces vascular permeability, angiogenesis and arteriogenesis in a rabbit hindlimb ischemia model. FASEB J. 17, 100-102.
22. SCHAPER, W., and SCHOLZ, D. (2003). Factors regulating arteriogenesis. Arterioscler. Thromb. Vasc. Biol. 23, 1143-1151.
23. SCHULICK, A.H., VASSALLI, G., DUNN, P.P., DONC, G., RADE, J.J., ZAMARRON, C., and DICHEK, D.A. (1997). Established immunity precludes adenovirus-mediated gene transfer in rat carotid arteries: Potential for immunosuppression and vector engineering to overcome barriers of immunity. J. Clin. Invest. 99, 209-219.
24. SHYU, K.G., CHANG, H., WANG, B.W., and KUAN, P. (2003). Intramuscular vascular endothelial growth factor gene therapy in patients with chronic critical leg ischemia. Am. J. Med. 114, 85-92.
25. TAKESHITA, S., PU, L.Q., STEIN, L.A., SNIDERMAN, A.D., BUNTING, S., FERRARA, N., ISNER, J.M., and SYMES, J.F. (1994). Intramuscular administration of vascular endothelial growth factor induces dose-dependent collateral artery augmentation in a rabbit model of chronic limb ischemia. Circulation 90, II228-II234.
26. THIRION, C., LAROCHELLE, N., VOLPERS, C., DUNANT, P., STUCKA, R., HOLLAND, P., NALBANTOGLU, J., KOCHANEK, S., and LOCHMULLER, H. (2002). Strategies for muscle-specific targeting of adenoviral gene transfer vectors. Neuromuscul. Disord. 12(Suppl. 1), S30-S39.
27. YANG, H.T., DESCHENES, M.R., OGILVIE, R.W., and TERJUNG, R.L. (1996). Basic fibroblast growth factor increases collateral blood flow in rats with femoral arterial ligation. Circ. Res. 79, 62-69.